Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kezar Life Sciences Inc
KZR | US
7.37
USD-0.01
-0.14%
KZR | US
About Kezar Life Sciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/04/2026
Close
7.37
Open
7.35
High
7.51
Low
7.35
Kezar Life Sciences Inc. a clinical-stage biotechnology company engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616) a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications including lupus nephritis dermatomyositis and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261 a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco California.
View LessKZR | US
Risk
72.4
Sharpe
0.96
Luna's Score
54/100
Recommendation
Hold
Luna says (KZR | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
7.3%1 month
72.4%3 months
49.0%6 months
83.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.40
Debt to equity
0.12
Debt to assets
0.10
Ent. to EBITDA
0.06
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-98.46M
MarketCap
537.73M
MarketCap(USD)
537.73M
Div. yield
-
Op. margin
-1.42K
Erngs. growth
-
Rev. growth
-
Ret. on equity
-51.48
Short ratio
0.92
Short perc.
1.38
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.22
Range1M
1.47
Range3M
1.52
Volumes: Market Activity
Rel. volume
1.34
Price X volume
1.21M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.06 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.40 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 49.03 | - | Lower Risk |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 537.73M | - | Emerging |
